Inventia Life Science | The Culture Newsletter — November 2025
Edition
Advancing Drug Discovery With Scalable 3D Biology
Welcome
to the November edition of The
Culture, your monthly roundup of scientific insights,
practical resources, and real-world applications of 3D biology.
This
month, we’re focusing on how high-fidelity
3D cancer models are reshaping modern drug discovery and translational
oncology. From new blog features on organoids, the
tumor microenvironment, and reproducible 3D workflows to our upcoming
presence at Cell
Bio 2025 (ASCB | EMBO) and an on-demand webinar
exploring Drug
Discovery 2.0, this edition is packed with tools to
help you scale human-relevant models with confidence.
Whether you're designing multi-matrix tumor–stroma
systems, analyzing immune infiltration, or integrating patient-derived
models into screening workflows, you’ll find timely resources to
support your research.
|
|
|
Inventia
Insights: User Stories and Guides from the Blog
How
Bio-Printed Cancer Organoids Are Reshaping Drug Discovery
Discover how researchers at the University of Florida
are engineering patient-derived cancer organoids using RASTRUM™ to
build reproducible, biologically relevant 3D models for
high-throughput phenotypic screening and precision oncology.
Read the story →
Creating dynamic tumor microenvironments with 3D cell
models
The tumor microenvironment (TME) plays a critical role
in therapeutic response, but it’s difficult to capture in traditional
systems. This post explores how matrix-embedded 3D models, tunable
stiffness, and co-cultures enable more realistic TME modeling for drug
discovery.
Explore the article →
Reproducible and Scalable 3D Cell Models: A New Era for
Drug Discovery
Drug discovery teams need models that are both
biologically relevant and operationally practical. Learn how RASTRUM
enables reproducible, high-throughput 3D systems that deliver
consistent data across plates, assays, and campaigns.
Read the full story →
|
|
|
Resource
Spotlight: The Tumor
Microenvironment in Phenotypic Drug Discovery
Phenotypic screening depends on models that capture the
complexity of the tumor microenvironment — without sacrificing
throughput or usability.
In this guide, you’ll find:
- Key requirements for
physiologically relevant 3D models
- How matrix-embedded
architectures support meaningful tumor–stromal interactions
- Practical
considerations for imaging, assay compatibility, and downstream
analysis
- How the RASTRUM
Platform integrates complexity and usability in high-throughput
workflows
Download the guide →
|
On-Demand
Webinar: Drug
discovery 2.0: integrating high-fidelity 3D cancer models at scale
using RASTRUM
Originally presented at the October
2025 Drug Discovery News Virtual Symposium, this
on-demand webinar explores how high-fidelity 3D cancer models are
transforming modern drug discovery workflows.
Inventia Life Science Application Lead Sean Porazinski, Ph.D.
demonstrates how RASTRUM™ enables:
- Precise, scalable,
reproducible 3D cancer models using dual and triple matrix
architectures
- Immune cell
infiltration studies revealing T-cell access and tumor killing in
3D environments not possible with 2D or BME systems
- High-throughput
pancreatic cancer (PDAC) screening in 96- and 384-well formats
- Integration of
patient-derived tumoroids to support precision medicine programs
- Biomarker-driven
insights such as LCN2-associated itraconazole sensitivity
- Rapid assay
development, imaging, and downstream analysis for high-content
oncology discovery
Watch the recording →
|
|
|
Razza's Tip of
the Month: Giving Thanks for 3D Biology
Wishing
my friends in the US and those around the globe who celebrate a Happy
Thanksgiving!
This year, I’m grateful for reproducible, phenotypically
relevant 3D cell models created using the RASTRUM
platform.
Nothing warms a bioprinter’s heart like consistent data, mate.
Catch ya in the workflow,
– Razza
|
|
|
|
|
